Adverse events of PARP inhibitors in the treatment of advanced or recurrent ovarian cancer: A real-world study

Abstract

Synopsis: Objective: To examine adverse events related to different PARP inhibitor maintenance therapies in patients with advanced or recurrent ovarian cancer.Key words: ovary, retrospective observational study, PARP inhibitors, maintenance therapy, adverse event

Methods: This study targeted patients treated with PARP inhibitor maintenance therapies from 2019 to 2022. The therapies included olaparib (O group), niraparib (N group), and a combination of olaparib and bevacizumab (P group). We evaluated the rates of treatment interruption, dose reduction, and discontinuation, as well as the incidence of grade 3 or higher hematotoxicity.

Results: A total of 319 cases were examined. The rates (%) of interruption, dose reduction, and discontinuation for initial treatment in the O, N, and P groups were 60/72/69 (NS: not significant), 42/47/51 (NS), and 6/7/2 (NS) respectively. Grade 3 or higher adverse events were anemia 15/12/12 (NS) and neutropenia 15/16/10 (NS). Thrombocytopenia was 0/10/0 (p＝0.009), showing a significant difference between the three groups.

Conclusion: No significant difference was found in the rates of interruption, dose reduction, or discontinuation among the three groups. A significant difference was observed in grade 3 or higher thrombocytopenia. All PARP inhibitor maintenance therapies were considered to be safely administered.